Letter: In brief (1)

Your article on rational drug design (Features: research, THES , October 26) gave a good summary of current thinking about chemical modelling, given increasing costs in moving drugs through the development process. Only a small percentage of drugs make it from the laboratory bench to preclinical or phase-one trials, let alone go on to be proved efficacious and end up on the pharmacists' shelf.

Mark Lipscombe
Project manager
Origin Pharmaceutical Services Ltd